The FDA on August 8, 2025, approved Voriconazole Oral Suspension (ANDA211598) from Camber Pharmaceuticals, Inc., positioning the company to capture significant market share in the antifungal space. This approval addresses a critical need for patient-friendly formulations and allows Camber to enter a competitive segment driven by rising demand for generic alternatives.